Company / EPS (Diluted)
Intellia Therapeutics, Inc. EPS (Diluted) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$5.42
FY2025
5-year range
-$6.16 / -$2.11
FY2021-FY2025
Trend
+12.0%
vs FY2024
Sector context
#150 of 159
Health Care
What the data says
Among 159 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 6% for eps (diluted). EPS (Diluted) returned to growth in FY2025 after 6 years of decline, reaching $-5.42.
Based on SEC 10-K filings.
-5.42 in FY2025.
Declined from $-3.78 to $-5.42 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 159This company -$5.42 Sector average $1.64
▼
-430.8% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 12.0% year-over-year.
- Ranks #150 out of 159 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2018.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.42 | +12.0% |
| FY2024 | -$6.16 | -63.0% |
| FY2023 | -$3.78 | -57.5% |
| FY2022 | -$2.40 | -13.7% |
| FY2021 | -$2.11 | -6.6% |
| FY2020 | -$1.98 | -5.3% |
| FY2019 | -$1.88 | -32.4% |
| FY2018 | -$1.42 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026